

## **Anne McDonald Pritchett, PhD**

Dr. Pritchett currently serves as Vice President in the Policy and Research Department at PhRMA where she is responsible for the development and implementation of legislative, regulatory and advocacy strategies focused on advancing policies to foster continued medical innovation and her unit is responsible for managing a range of research activities focused on the value of innovation, the importance of regulatory and intellectual property incentives, the vibrant R&D ecosystem and the economic impacts of the innovative biopharmaceutical industry. She has focused on a range of issues related to the review and approval of new medicines in her almost 12 years with the organization. Prior to joining PhRMA, she served in a senior policy role in the White House Drug Policy office for almost 8 years.

### **Pharmaceutical Research and Manufacturers of America (PhRMA), Vice President, Policy and Research (2005-Present)**

- Oversees development of public policy related to promoting biomedical innovation, including global intellectual property and other incentives necessary to foster research investments, regulatory issues related to the biopharmaceutical lifecycle, the research and development ecosystem, and competitiveness issues as well as issues related to prescription drug abuse.
- Manages a broad portfolio of economic and policy research, with a focus on key aspects of the R&D ecosystem, industry economics, the pipeline and the value of medicines.
- Serves as industry spokesperson externally on industry-related issues.
- Manages the organization's annual strategic planning process which is focused on setting priorities to foster effective advocacy for public policies that encourage the discovery of important, new medicines for patients by biopharmaceutical research companies.
- Served for several years as Deputy Vice President, Strategic Planning and Biopharmaceutical and Innovation Policy, with a primary focus on leading strategic planning and policy development focused on incentives for innovation and biologics issues.

### **White House Drug Policy Office, Senior Policy Analyst/Evaluation Advisor (1997- 2005)**

- For the Planning and Research Branch, Office of Planning and Budget, responsible for policy research and analysis related to the nature and extent of the use and abuse of illegal drugs and the diversion of and abuse and mis-use of prescription medicines.
- Contributed to the National Drug Control Strategy and Budget and assessed and reported progress toward key national goals and objectives. Support included engaging in interdepartmental meetings with the more than 30 agencies receiving drug control monies to build consensus around goals and objectives.

- Oversaw the evaluation the National Youth Anti-Drug Media Campaign and related research and evaluation activities including serving as a liaison to the National Institute on Drug Abuse and the Campaign's Behavioral Change Expert panel.
- Provided research support for the Counterdrug Technology Assessment Center including overseeing research evaluating the use of innovative technologies to improve the reliability of estimates of illegal drugs.
- Oversaw a range of qualitative and quantitative research efforts including an ethnographic research program to detect emerging trends in drug abuse and a multi-year research effort conducted by the National Academy of Sciences on the state of data and research related to drug abuse.

**American Medical Women's Association, Director of Public Affairs and Government Relations (1995- 1997)**

- Managed the public affairs and government relations departments for a national nonprofit organization to promote the personal and professional development of women physicians and conduct advocacy on a wide range of public health issues.
- Oversaw a range of public health education efforts, e.g., public awareness related to heart disease in women, thyroid conditions, and a range of chronic diseases.
- Drafted testimony on key public health issues and represented the organization externally on a range of health care issues.
- Developed policy recommendations for Executive Committee and Board approval, supported advocacy days, and developed interim meeting programs and presented at annual meetings on a range of issues including medical privacy.

**Cygnus Corporation, Senior Associate/Project Director (1993-1995)**

- Managed a range of communications and research contracts for several federal government agencies, including the National Institute on Drug Abuse, National Institute of Alcohol Abuse and Alcoholism, other Department of Health and Human Services entities, and the National Institute of Justice.
- Managed a range of support contracts with the Centers for Disease Control and Prevention, including staffing two Surgeon General's reports and supporting the first Anti-Tobacco Campaign Media Resource Center as well as providing strategic, writing, and research support to the National Institute of Justice.

**CSR, Incorporated, Director, Editorial Services Group, Senior Editor-Writer/Production Coordinator, Editor-Writer/Researcher (1990-1991), Editorial Assistant (1990-1993)**

- Managed a large publications and proposal coordination department for a contract research firm.
- Responsibilities included hiring and managing staff, subcontractors, various experts and consultants, and negotiating budgets and salaries.

- Provided range of research and other support for a contract with the White House Drug Policy Office.
- Gained subject matter expertise and strong knowledge in a range of issue areas including elder care, biomedical research, health care financing, substance abuse, and health communications.

**EDUCATION**

Virginia Polytechnic Institute and State University	Ph.D.	Public Administration and Policy	2005
George Mason University	M.P.A.	Public Policy	1997
Virginia Polytechnic Institute and State University	B.A.	English Graphic Design	1989